HRT Financial’s Cognition Therapeutics CGTX Stock Holding History

HRT Financial’s Portfolio CGTX Stock Details CGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-152,999	Closed	-$116K	–	4321
2026 Q1	$116K	Buy	+152,999	New	+$178K	﹤0.01%	3322

Other funds holding CGTX

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

HCM

Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

HRT Financial's CGTX Position: Q2 2026 in Review

HRT Financial sold out of Cognition Therapeutics (CGTX) in Q2 2026, closing a stake of 152,999 shares — an estimated $116K sold.

HRT Financial first reported a position in CGTX in Q1 2026 and held it in 1 quarter. The position peaked at $116K in Q1 2026. 66 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

HRT Financial reported no remaining Cognition Therapeutics position as of Q2 2026 after selling out during the quarter.
HRT Financial sold 152,999 Cognition Therapeutics shares in Q2 2026, an estimated $116K.
HRT Financial first reported a position in Cognition Therapeutics in Q1 2026 and held it in 1 quarter.
HRT Financial's Cognition Therapeutics position peaked at $116K in Q1 2026.
66 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.